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Abstract
Background: Human prostate cancer represents one of the most frequently diagnosed cancers in men worldwide.
Currently, diagnostic methods are insufficient to identify patients at risk for aggressive prostate cancer, which is
essential for early treatment. Recent data indicate that elevated cholesterol levels in the plasma are a prerequisite
for the progression of prostate cancer. Here, we analyzed clinical prostate cancer samples for the expression of
receptors involved in cellular cholesterol uptake.
Methods: We screened mRNA microarray files of prostate cancer samples for alterations in the expression levels of
cholesterol transporters. Furthermore, we performed immunohistochemistry analysis on human primary prostate
cancer tissue sections derived from patients to investigate the correlation of SR-BI with clinicopathological
parameters and the mTOR target pS6.
Results: In contrast to LDLR, we identified SR-BI mRNA and protein expression to be induced in high Gleason
grade primary prostate cancers. Histologic analysis of prostate biopsies revealed that 53.6 % of all cancer samples
and none of the non-cancer samples showed high SR-BI staining intensity. The disease-free survival time was
reduced (P = 0.02) in patients expressing high intra-tumor levels of SR-BI. SR-BI mRNA correlated with HSD17B1 and
HSD3B1 and SR-BI protein staining showed correlation with active ribosomal protein S6 (RS = 0.828, P < 0.00001).
Conclusions: We identified SR-BI to indicate human prostate cancer formation, suggesting that increased levels of
SR-BI may be involved in the generation of a castration-resistant phenotype.
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Background
Prostate cancer is one of the most common solid organ
tumors in males. It is a slow growing type of tumor, but
can potentially give rise to aggressive and metastasizing
forms of cancer [1]. The risk for prostate cancer increases
with consumption of a high fat, high cholesterol diet or
the presence of hypercholesterolemia [2–4]. Very recently,
it was shown that the accumulation of esterified choles-
terol underlies the aggressiveness of human prostate can-
cer [5]. Cellular cholesterol is either synthesized by the
cells themselves, or exogenous cholesterol is taken up and
utilized by the cancer cells. Cholesterol uptake is mainly
mediated by the high density lipoprotein receptor SR-BI
and the low density lipoprotein receptor LDLR [6–9]. In
normal tissue, SR-BI is expressed in the liver and in ste-
roidogenic tissues, where cholesterol uptake is necessary
for steroid hormone synthesis [10–13]. Notably, patients
suffering from mutations in cla-1, the human homolog to
SR-BI, display impaired steroid hormone synthesis [14].
There is evidence that SR-BI plays a role in prostate
cancer development, specific antigen secretion and the
viability of prostate cancer cells because it was shown that
SR-BI-specific knockdown in LNCaP and C4-2 prostate
carcinoma cells reduced PSA secretion and the viability of
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prostate cancer cell lines [15]. Therefore, this study aimed
to evaluate the expression of receptors involved in




For Gleason score analysis, the GSE2109 and GSE3933
datasets from the International Genomics Consortium
Expression Project for Oncology were used [16]. The sam-
ple sizes were as follows: GSE2109, n = 56 (Gleason score ≤
6 n = 20, Gleason score ≥ 7 n = 36), GSE3933, n = 58 for
SR-BI (Gleason score ≤ 6 n = 24, Gleason score ≥ 7 n = 34)
and n = 60 for LDLR (Gleason score ≤ 6 n = 24, Gleason
score ≥ 7 n = 36). For metastasis analysis, the GSE35988,
GSE3933 and GSE6919 datasets were used [16–19]. The
sample sizes were as follows: GSE35988, n = 94 (primary
site n = 59, metastasis n = 35), GSE3933, n = 68 for SR-BI
(primary site n = 59, metastasis n = 9) and n = 68 for LDLR
(primary site n = 61, metastasis n = 7) and GSE6919, n = 88
(primary site n = 64, metastasis n = 24). For Kaplan-Meier
analysis, the GSE40272 dataset was used (sample size:
n = 85) [20].
Patient cohort and pathology
With institutional review board approval from the
Medical University of Vienna (EK Nr: 1734/2014), tissue
microarrays were obtained from US Biomax (Rockville,
MD). All samples were formalin-fixed less than 10 min
after surgery, paraffin embedded and assembled as cores
with a diameter of 1.5 mm. Tissue sections were quality
controlled and contained normal prostate tissue and pros-
tate cancer tissue, representing different stages of disease
progression. Each individual core was assigned to inde-
pendent Gleason scoring and was reviewed by two board-
certified pathologists.
Immunohistochemistry
Prostate cancer tissue sections containing paraffin-
embedded samples were melted for 20 min at 60 °C
and rehydrated by subsequent incubation in Xylol,
Isopropanol, 96 % Ethanol, 70 % Ethanol and 50 %
Ethanol. Then, tissue sections were washed and heated
to 120 °C in a pH 6.0 buffer or a pH 9.0 buffer (Dako,
Glostrup, Denmark), depending on the antibody. After
cooling to room temperature, samples were incubated
with 1 % H2O2 (Sigma, St. Louis, MO) for 10 min.
Afterwards, samples were permeabilized with 0.1 %
Triton X-100 (Sigma) for 5 min. Then, sections were
blocked with 2.5 % horse sera (Vector Laboratories,
Burlingame, CA) for at least 20 min at room temperature.
Subsequently, sections were incubated overnight at 4 °C
with the primary antibodies directed against SR-BI
(BD Transduction Laboratories™, Franklin Lakes, NJ),
LDLR (Santa Cruz Biotechnology, Santa Cruz, CA)
and pS6 (Cell Signaling Technology, Beverly, MA),
diluted 1:200. For negative control staining, sections were
incubated with matched isotope control antibodies instead
of primary antibodies. Next, slides were washed and the
corresponding secondary, biotinylated antibodies (Vector
Laboratories) were added for 45 min at room temperature.
After a washing step, sections were incubated for 30 min
with Streptavidin-HRP (Leica, Wetzlar, Germany). For de-
tection, tissue sections were incubated with AEC+ High
Sensitivity Substrate Chromogen (Dako). Counterstaining
with hematoxylin solution was performed according to
Mayer (Carl Roth, Karlsruhe, Germany); tissue sec-
tions were mounted with Aquatex® (Merck Millipore,
Billerica, MA).
Evaluation of immunohistochemical staining
Evaluation of tissue sections was performed by two inde-
pendent researchers who were blinded to the patients’
details. Immunostaining of the anti-SR-BI antibody was
scored on at least duplicate tissues using the following
arbitrary scale: no staining (0), low staining (1), medium
staining (2) and high staining (3).
Statistical analysis
Dot plots were generated with SPSS v21. The arithmetic
mean of all samples is indicated by a line. Two-tailed P-
values were calculated with unpaired (independent) t-tests
in SPSS. P-values ≤ 0.05 were considered to be statistically
significant. The significance of the difference between the
variances of two samples was determined with Levene’s
test. If the resulting P-value of Levene’s test was > 0.05, we
assumed equal variances and adopted the output of the
equal variance t-test as the P-value; if the resulting P-value
of Levene’s test was ≤ 0.05, we assumed unequal variances
and adopted the output of the unequal variance t-test as
the P-value.
Scatter plots were generated with SPSS v21. Pear-
son correlation analysis was performed to calculate
the P-values of the graphs.
For analysis of immunohistological staining results, the
internet tool VassarStats (http://vassarstats.net/index.html)
was used. Risk ratios were calculated using 2 × 2 contin-
gency tables and the chi-square test was applied to deter-
mine the association of clinicopathological parameters
with SR-BI expression.
Kaplan-Meier analysis and the log-rank test were
performed using SPSS 21 to test the association of SR-
BI and LDLR with disease-free survival time. A total
of 85 samples were available for evaluation. For the
analysis, samples were segregated into groups with SR-
BI or LDLR levels above (42 samples) and below or
equal (43 samples) to the median value.
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Results
Evaluation of SR-BI and LDLR expression as markers for
prostate cancer progression
We analyzed SR-BI and LDLR mRNA expression in
primary human prostate cancers from the Expression
Project for Oncology and from a hallmark study by
Lapointe et al. [16]. When comparing prostate cancer
samples with high Gleason scores (equal to or higher
than 7) and samples with low Gleason scores (equal
to or lower than 6), SR-BI was more highly expressed
in GSE2109 (n = 56, P = 0.039, Fig. 1a) and GSE3933
(n = 58, P = 0.016, Fig. 1c). LDLR was not increased in
Fig. 1 Expression of SR-BI and LDLR in clinical prostate samples. Differential expression of SR-BI and LDLR according to Gleason scoring (a–d). All samples
were grouped according to Gleason score (GS)≤ 6 and≥ 7. Differential expression of SR-BI and LDLR in metastasizing and non-metastasizing prostate
tissues (e-j). All samples were grouped into primary tumors (primary site) and metastasizing tumors (metastasis). P-values are presented within each graph.
The arithmetic mean is given as a line within the dots. Data displayed as log 2 median-centered intensity
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high Gleason score samples in GSE2109 (n = 56, P = 0.844,
Fig. 1b) and in GSE3933 (n = 60, P = 0.219, Fig. 1d).
The most important parameter used to decide upon
patient survival is the occurrence of metastasis. There-
fore, we next determined the expression of SR-BI and
LDLR in clinical prostate samples derived either from
non-metastatic or metastatic prostate cancer. For this
analysis, we investigated the dataset GSE35988, which
contains benign and localized prostate cancer from
radical prostatectomy as well as metastatic, castration-
resistant prostate cancer obtained from rapid autopsy
[17]. Furthermore, we included the datasets GSE6919
and GSE3933, which contain samples from the pri-
mary tumor site as well as metastasized prostate can-
cer samples from the liver, lung, kidney, adrenal gland
or lymph nodes [16, 18, 19]. We identified an in-
creased expression of SR-BI in metastatic prostate
samples compared to non-metastatic prostate samples in
GSE35988, GSE3933 and GSE6919 (P < 0.001, P = 0.009
and P = 0.017, respectively) (Fig. 1e, g, i,). Contrary to SR-
BI, LDLR expression was not increased in metastatic pros-
tate samples compared to non-metastatic prostate samples
in GSE35988, GSE3933 and GSE6919 (P = 0.341, P = 0.139
and P = 0.856, respectively) (Fig. 1f, h, j).
Association of clinicopathological parameters with
SR-BI expression
To confirm findings from mRNA expression studies, we
assessed SR-BI protein expression in normal prostate
tissue and prostate cancer samples derived from patients
with known TNM status. A total of 106 biopsy cores were
independently assigned to Gleason scoring. Cores were
subjected to immunohistochemical staining for SR-BI and
afterwards analyzed for their staining intensity. Table 1
shows the clinicopathological characteristics of the cohort
studied. Samples were classified into non-cancer and can-
cer samples. Cancer samples were further characterized
by Gleason score, pathologically classified tumor stage
(pT) and metastasis. Nearly half of all cancer samples
showed a Gleason score equal to or above 7. Furthermore,
about a third of all cancer samples showed advanced
tumor stages (pT3/4), and nearly half of them were posi-
tive for metastasis. Representative cores for different stain-
ing intensities of SR-BI and their respective scores are
shown in Fig. 2 (a–d). We tested the specificity of our
antibodies by staining human liver sections (Fig. 2e and f).
The distribution of the results for the whole tissue col-
lective is shown in Fig. 2g. On the basis of a binary
classification system for low (score 0 and score 1) and
high (score 2 and score 3) SR-BI staining intensities, we
evaluated associations between SR-BI and the presence
or absence of clinicopathological parameters. Notably,
out of 23 normal prostate samples, none showed high
staining results (score 2 and score 3), and among all
cancer samples, approximately 53.6 % showed high
staining for SR-BI.
As shown in Table 2, we identified high SR-BI expression
to be associated with the presence of prostate cancer when
compared to non-cancer prostate tissue (risk ratio = 2.154,
P < 0.0001). Furthermore, we identified an association of
high SR-BI score with a Gleason score equal to or higher
than 7 (risk ratio = 2.907, P < 0.0001).
Because SR-BI expression showed an association with
prostate cancer differentiation, we also tested for LDLR
expression on selected sections with either low or high
SR-BI staining intensity (Fig. 3a–d). Our case study
showed that LDLR was constitutively expressed in
prostate tissue, with lower expression levels in high-
grade cancer samples. Interestingly, we also observed
cases of low-grade prostate cancer, which displayed
high SR-BI expression in a subpopulation of cells showing
signs of tissue invasion (Fig. 3e and f). Cancer cells of this
subpopulation either grew detached from the primary
tumor, floating in the remaining glands (Fig. 3e), or sepa-
rated from the solid tumor mass, infiltrating the surround-
ing tissue (Fig. 3f).
To assess whether SR-BI and LDLR had any influence
on the clinical outcome of patients, we chose to evaluate
the disease-free survival time in relation to SR-BI and
LDLR expression. Therefore, we performed Kaplan-
Meier analyses of the dataset GSE40272, which con-
tained mRNA expression data on prostate tissue samples
from men who underwent radical prostatectomy [20].
The disease-free survival time was defined as the time
between surgery and the recurrence of disease (serum
PSA > 0.1 ng/ml on two consecutive measurements after
surgery). We identified samples with low SR-BI expres-
sion to have a significantly better survival outcome com-
pared to samples with high SR-BI expression (p = 0.02,
Fig. 3h). By contrast, there was no significant difference
in disease-free survival time between samples with low
LDLR expression and samples with high LDLR expres-
sion (Fig. 3g).
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Fig. 2 Immunohistochemical staining of prostate tissue and control tissue for SR-BI expression. Each panel shows representative prostate samples scored
for staining intensity as follows: 0 for negative (a), 1 for low (b), 2 for moderate (c) and 3 for high (d). Liver sections were used as positive controls (pos. ctrl.)
in standard magnification (e) and in high magnification (high mag.), demonstrating SR-BI localization in the outer cell membrane of hepatocytes (f). The
overall scoring distribution for SR-BI staining intensity in different clinicopathological groups (g). Scores of 0 and 1 represented “low” expression and are
shown in green colors, whereas scores of 2 and 3 represented “high” expression and are shown in blue colors. Clinicopathological groups are plotted on
the x-axis: non-cancer and cancer, Gleason score (GS)≤ 6 and≥ 7, pathologic tumor stage 2 (pT2) and pathologic tumor stage 3/4 (pT3/4), metastasis
negative (met. neg.) and metastasis positive (met. pos.)
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Correlation of SR-BI with androgen-synthesizing enzymes
and the mTOR pathway
Because SR-BI mediates the selective uptake of cholesterol,
which can be used for steroidogenesis, we analyzed en-
zymes that participate in androgen synthesis. We identified
the β-hydroxysteroid-dehydrogenases HSD17B1 and
HSD17B3 to be significantly up-regulated in meta-
static compared to non-metastatic prostate cancer;
they also correlated with the intensity of SR-BI expres-
sion (Fig. 4a–h).
Table 2 Evaluation of the prognostic significance of SR-BI staining
intensity
Variable P-value Risk ratio 95 % Confidence interval
Cancer vs. non-cancer <0.0001 2.128 1.693–2.675
GS≥ 7 vs. GS≤ 6 <0.0001 2.907 1.673–5.050
pT3/pT4 vs. pT2 0.371 1.269 0.739–2.182
Met. pos. vs. met. neg. 0.207 1.351 0.837–2.182
Fig. 3 Lipoprotein receptor expression patterns in prostate cancer (high grade and low grade). Histologic staining for LDLR and SR-BI in selected
patients. Tissue derived from a 27-year-old patient diagnosed with prostate hyperplasia was stained for LDLR (a); a consecutive area of the same
tumor was stained for SR-BI (b). Tissue derived from a 75-year-old patient diagnosed with prostate cancer T2N1M1c and Gleason score 5 + 4 was
stained for LDLR (c); a consecutive area of the same tumor was stained for SR-BI (d). Tumor biopsies from a 72-year-old patient diagnosed with
prostate cancer T2N0M0 and Gleason score 3 + 3 were analyzed for SR-BI expression (e and f). Black arrows indicate clusters of cells strongly positive
for SR-BI. Kaplan Meier analysis of LDLR and SR-BI expression in GSE40272 (g–h). High LDLR expression had no effect on disease-free survival time
(g). High SR-BI expression was associated with decreased disease-free survival time (h). Green = high expression (high), blue = low expression
(low), DFS = disease-free survival time. P-values of the log-rank test are presented within each graph
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Fig. 4 (See legend on next page.)
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Mechanistic studies have shown that mTOR signal-
ing can mediate androgen independence [21]. There-
fore, we further assessed the association of SR-BI
expression with serine phosphorylation of ribosomal
protein S6 at position 240 and 244. A total of 22
biopsy cores were subjected to immunohistochemical
staining for pS6, and adjacent sections from the same
patients were simultaneously subjected to SR-BI stain-
ing. Representative histologic staining for high grade
and low grade prostate carcinoma samples is shown in
Fig. 4 (i–l). After the pS6 and SR-BI staining, the sam-
ples were analyzed for their staining intensity. Repre-
sentative cores for different staining intensities of pS6
and their respective scores are shown in Additional
file 1: Figure S1 (A–D). Spearman correlation analysis
revealed a significant positive correlation of SR-BI and
pS6 (R = 0.828, p < 0.001).
Discussion
Prostate cancer is the most commonly diagnosed malig-
nancy in men and it has the potential to progress to a
metastatic and highly aggressive form of cancer, which is
still difficult to cure. Therefore, it is of profound import-
ance to identify markers that allow the prediction of
prostate cancer progression to its aggressive metastatic
form. Recent studies suggest that cholesterol plays a
major role in prostate cancer [15, 22–24]. In human
cells, cholesterol uptake is mainly based on two path-
ways: receptor-mediated endocytosis by the LDL recep-
tor and selective lipid uptake by SR-BI [6–8]. Here, we
show an association of prostate cancer malignancy with
the expression of the HDL receptor SR-BI. Our analysis
of 306 clinical prostate samples for mRNA and 106
prostate tissue biopsy cores for protein expression iden-
tified significantly higher SR-BI expression in high Glea-
son grade versus low Gleason grade prostate cancer
samples. Furthermore, our analysis of gene expression
profiles identified significantly higher SR-BI mRNA
expression in metastatic compared to non-metastatic
prostate cancer. Strikingly, we further discovered an
association of SR-BI expression with disease-free sur-
vival time in a cohort of 85 clinical prostate samples.
Previous studies already suggested a connection of SR-
BI expression with prostate cancer: the knockdown of
SR-BI has been shown to reduce PSA levels and the
viability of prostate cancer cells in vitro [15]. More-
over, SR-BI was found to be significantly up-regulated
with progression to lethal castration-resistant prostate
cancer (CRPC) in an LNCaP xenograft mouse model
[25], while androgen-tolerant LNCaP cells in vitro did
not show SR-BI up-regulation [26]. SR-BI has further
been linked to nasopharyngeal cancer [27], colorectal
cancer [28], ovarian cancer [28] and most notably
breast cancer [29, 30], a tumor strongly dependent on
the synthesis of sexual hormones. Furthermore, it was
demonstrated that mutations of SR-BI affected the
proliferation and apoptosis of the breast cancer cell
line MCF-7 [30]. Knockdown of SR-BI was shown to in-
hibit proliferation and migration in breast cancer, and SR-
BI knockdown also caused a decrease of tumor growth in
MDA-MB231 and MCF-7 breast cancer cells in vivo when
injected into nude mice [29].
The mTOR pathway plays a key role in the regulation
of cellular growth and metabolism [31, 32]. Together
with raptor and LST8, mTOR forms a complex called
mTORC1 (mTOR complex 1), which acts by activating
the ribosomal protein S6 through the protein kinase
S6K1 [31, 32]. It is further known that mTORC1 influ-
ences cholesterol synthesis and uptake via the SREBP
pathway [33–35]. Recently, it was shown that the in-
hibition of mTOR via rapamycin down-regulates SR-BI
expression in human umbilical vein endothelial cells,
indicating a direct connection between mTOR activa-
tion and SR-BI expression [36]. Further, it is known
that mTOR plays a crucial role in the progression of
prostate cancer to CRPC by influencing the androgen
signaling pathway [37, 38]. According to our results,
pS6 expression significantly correlates with SR-BI ex-
pression, which suggests the regulation of SR-BI by
mTORC1 in prostate cancer.
To our knowledge, SR-BI has not been thoroughly
studied in clinical samples of prostate cancer, and our
findings on the mRNA and protein expression of SR-BI
can contribute substantially to our understanding of pros-
tate cancer progression. This study demonstrates the high
expression of SR-BI in de-differentiated and metastasized
Fig. 4 Correlation of SR-BI with androgen-synthesizing enzymes and the mTOR pathway. Differential expression of HSD17B1 and HSD3B1 in primary
tumors (primary site) and metastasizing tumors (metastasis) (a, c, e, g). The arithmetic mean is given as a line within the dots and the P-values of t-test
analysis is given within each graph. Scatter plots correlating SR-BI expression with HSD17B1 and HSD3B1 in prostate cancer (b, d, f, h). P-values of Pearson
correlation analyses and regression lines are presented within each graph. Red dots represent metastatic and blue dots represent non-metastatic prostate
cancer. Analysis of the co-occurrence of SR-BI and ribosomal protein S6 phosphorylation (i–l). A representative high grade prostate cancer is shown
with staining for SR-BI (i) and for S6 phosphorylation at serine 240 and 244 in a consecutive area of the same tumor (j). A representative
low grade prostate cancer is shown with staining for SR-BI (k) and for S6 phosphorylation at serine 240 and 244 in a consecutive area of
the same tumor (l). pS6 = ribosomal protein S6 phosphorylation at serine 240 and 244
Schörghofer et al. Reproductive Biology and Endocrinology  (2015) 13:88 Page 8 of 10
prostate cancer, which almost always acquires resist-
ance to androgen depletion. Therefore, we suggest that
increased levels of SR-BI are involved in the transport
of cholesterol into the tumor cell. This uptake of choles-
terol could be exploited by the cancer cell to up-regulate
its androgen synthesis. We observed the up-regulation of
3β- and 17β-hydroxysteroid dehydrogenases, which may
play an important yet unclear role in intra-tumoral andro-
gen synthesis [39, 40]. This process may contribute to the
generation of castration-resistant prostate cancer. There-
fore, pharmacologic inhibition of the HDL receptor might
represent a way to inhibit prostate cancer progression. We
suggest that SR-BI may be a valuable target for prostate
cancer therapy; therefore, we strongly recommend that
further studies investigate the role of SR-BI during pros-
tate cancer progression.
Conclusions
Here we have shown that the HDL receptor SR-BI can
be induced during the course of prostate cancer forma-
tion and progression. Intra-tumor expression was associ-
ated with an increase in Gleason scoring and also
metastatic prostate tissue showed SR-BI up-regulation
compared to primary tumor tissue. Importantly, we
identified positive correlation of SR-BI expression with
expression of androgen synthesizing enzymes and
mTOR activation.
Additional file
Additional file 1: Figure S1. Immunohistochemical staining of prostate
tissue for ribosomal protein phosphorylation at serine 240 and 244. Each
panel shows representative prostate samples scored for staining intensity
as follows; 0 for negative (A), 1 for low (B), 2 for moderate (C) and 3 for
high levels of pS6 (D). pS6 = ribosomal protein S6 phosphorylation at
serine 240 and 244. (JPEG 537 kb)
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